Hill-Rom Holdings, Inc. (NYSE: HRC) Stock Competitors & Peer Comparison
See HRC's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HRC and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HRC | $155.96 | +0.03% | 0 | 41.92 | $3.72 | +0.60% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
HRC vs BDX Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDX's P/E ratio is 11.62. In terms of profitability, HRC's ROE is +0.14%, compared to BDX's ROE of +0.05%. Regarding short-term risk, HRC is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
HRC vs BDXA Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDXA's P/E ratio is 45.70. In terms of profitability, HRC's ROE is +0.14%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, HRC is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
HRC vs MDLN Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MDLN's P/E ratio is 45.06. In terms of profitability, HRC's ROE is +0.14%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, HRC is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for HRC.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
HRC vs WST Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas WST's P/E ratio is 41.19. In terms of profitability, HRC's ROE is +0.14%, compared to WST's ROE of +0.19%. Regarding short-term risk, HRC is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for HRC.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
HRC vs HOLX Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HOLX's P/E ratio is 31.54. In terms of profitability, HRC's ROE is +0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HRC is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for HRC.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
HRC vs COO Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas COO's P/E ratio is 15.42. In terms of profitability, HRC's ROE is +0.14%, compared to COO's ROE of +0.03%. Regarding short-term risk, HRC is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for HRC.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
HRC vs BDXB Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HRC's ROE is +0.14%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, HRC is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
HRC vs BAX Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BAX's P/E ratio is 10.77. In terms of profitability, HRC's ROE is +0.14%, compared to BAX's ROE of -0.16%. Regarding short-term risk, HRC is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
HRC vs ATR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATR's P/E ratio is 23.13. In terms of profitability, HRC's ROE is +0.14%, compared to ATR's ROE of +0.14%. Regarding short-term risk, HRC is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
HRC vs AVTR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AVTR's P/E ratio is 13.46. In terms of profitability, HRC's ROE is +0.14%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, HRC is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for HRC.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
HRC vs RGEN Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RGEN's P/E ratio is 73.31. In terms of profitability, HRC's ROE is +0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, HRC is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for HRC.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
HRC vs TFX Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas TFX's P/E ratio is 12.32. In terms of profitability, HRC's ROE is +0.14%, compared to TFX's ROE of -0.28%. Regarding short-term risk, HRC is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for HRC.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
HRC vs BLCO Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BLCO's P/E ratio is 24.88. In terms of profitability, HRC's ROE is +0.14%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, HRC is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
HRC vs STVN Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STVN's P/E ratio is 31.81. In terms of profitability, HRC's ROE is +0.14%, compared to STVN's ROE of +0.10%. Regarding short-term risk, HRC is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for HRC.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
HRC vs MMSI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MMSI's P/E ratio is 19.01. In terms of profitability, HRC's ROE is +0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
HRC vs ICUI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ICUI's P/E ratio is 19.66. In terms of profitability, HRC's ROE is +0.14%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, HRC is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
HRC vs HAE Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HAE's P/E ratio is 15.86. In terms of profitability, HRC's ROE is +0.14%, compared to HAE's ROE of +0.11%. Regarding short-term risk, HRC is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for HRC.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
HRC vs XRAY Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas XRAY's P/E ratio is 9.04. In terms of profitability, HRC's ROE is +0.14%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, HRC is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for HRC.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
HRC vs LMAT Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LMAT's P/E ratio is 37.05. In terms of profitability, HRC's ROE is +0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, HRC is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for HRC.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
HRC vs PLSE Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas PLSE's P/E ratio is -27.48. In terms of profitability, HRC's ROE is +0.14%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, HRC is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for HRC.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
HRC vs ATRC Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, HRC's ROE is +0.14%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, HRC is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
HRC vs BLFS Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BLFS's P/E ratio is -141.85. In terms of profitability, HRC's ROE is +0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, HRC is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for HRC.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
HRC vs AZTA Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AZTA's P/E ratio is 60.82. In terms of profitability, HRC's ROE is +0.14%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, HRC is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for HRC.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
HRC vs KMTS Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas KMTS's P/E ratio is -8.92. In terms of profitability, HRC's ROE is +0.14%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, HRC is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for HRC.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
HRC vs STAA Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STAA's P/E ratio is 41.02. In terms of profitability, HRC's ROE is +0.14%, compared to STAA's ROE of -0.06%. Regarding short-term risk, HRC is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for HRC.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
HRC vs QDEL Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas QDEL's P/E ratio is 11.98. In terms of profitability, HRC's ROE is +0.14%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, HRC is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for HRC.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
HRC vs ATRI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HRC's ROE is +0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, HRC is less volatile compared to ATRI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
HRC vs ANGO Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ANGO's P/E ratio is -34.85. In terms of profitability, HRC's ROE is +0.14%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, HRC is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
HRC vs NNNN Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NNNN's P/E ratio is 145.38. In terms of profitability, HRC's ROE is +0.14%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, HRC is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for HRC.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
HRC vs OSUR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas OSUR's P/E ratio is -4.78. In terms of profitability, HRC's ROE is +0.14%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, HRC is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for HRC.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
HRC vs SMTI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas SMTI's P/E ratio is -426.00. In terms of profitability, HRC's ROE is +0.14%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, HRC is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
HRC vs UTMD Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas UTMD's P/E ratio is 19.86. In terms of profitability, HRC's ROE is +0.14%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for HRC.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
HRC vs INFU Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas INFU's P/E ratio is 23.97. In terms of profitability, HRC's ROE is +0.14%, compared to INFU's ROE of +0.14%. Regarding short-term risk, HRC is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for HRC.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
HRC vs KRMD Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas KRMD's P/E ratio is -95.75. In terms of profitability, HRC's ROE is +0.14%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, HRC is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for HRC.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
HRC vs PDEX Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas PDEX's P/E ratio is 19.34. In terms of profitability, HRC's ROE is +0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, HRC is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for HRC.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
HRC vs MBOT Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MBOT's P/E ratio is -6.58. In terms of profitability, HRC's ROE is +0.14%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, HRC is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for HRC.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
HRC vs AKYA Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AKYA's P/E ratio is -1.34. In terms of profitability, HRC's ROE is +0.14%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, HRC is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for HRC.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
HRC vs STSS Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STSS's P/E ratio is -0.02. In terms of profitability, HRC's ROE is +0.14%, compared to STSS's ROE of -1.66%. Regarding short-term risk, HRC is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for HRC.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
HRC vs DXR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas DXR's P/E ratio is 27.33. In terms of profitability, HRC's ROE is +0.14%, compared to DXR's ROE of +0.22%. Regarding short-term risk, HRC is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for HRC.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
HRC vs OMIC Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HRC's ROE is +0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, HRC is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for HRC.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
HRC vs IGAP Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HRC's ROE is +0.14%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, HRC is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for HRC.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
HRC vs NEPH Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NEPH's P/E ratio is 50.86. In terms of profitability, HRC's ROE is +0.14%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, HRC is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for HRC.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
HRC vs MLSS Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MLSS's P/E ratio is -6.50. In terms of profitability, HRC's ROE is +0.14%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, HRC is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for HRC.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
HRC vs POCI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas POCI's P/E ratio is -6.07. In terms of profitability, HRC's ROE is +0.14%, compared to POCI's ROE of -0.37%. Regarding short-term risk, HRC is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
HRC vs SDC Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas SDC's P/E ratio is -0.03. In terms of profitability, HRC's ROE is +0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HRC is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for HRC.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
HRC vs HBIO Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HBIO's P/E ratio is -16.81. In terms of profitability, HRC's ROE is +0.14%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, HRC is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for HRC.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
HRC vs IVC Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IVC's P/E ratio is -0.79. In terms of profitability, HRC's ROE is +0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HRC is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for HRC.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
HRC vs RVP Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RVP's P/E ratio is -2.06. In terms of profitability, HRC's ROE is +0.14%, compared to RVP's ROE of -0.08%. Regarding short-term risk, HRC is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for HRC.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
HRC vs ZJYL Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, HRC's ROE is +0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, HRC is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
HRC vs FEMY Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas FEMY's P/E ratio is -10.25. In terms of profitability, HRC's ROE is +0.14%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, HRC is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for HRC.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
HRC vs RGNT Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RGNT's P/E ratio is -0.08. In terms of profitability, HRC's ROE is +0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, HRC is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for HRC.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
HRC vs NSTG Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HRC's ROE is +0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HRC is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for HRC.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
HRC vs NXGL Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NXGL's P/E ratio is -1.13. In terms of profitability, HRC's ROE is +0.14%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, HRC is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for HRC.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
HRC vs POAI Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas POAI's P/E ratio is -0.03. In terms of profitability, HRC's ROE is +0.14%, compared to POAI's ROE of -107.05%. Regarding short-term risk, HRC is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for HRC.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
HRC vs LUCY Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LUCY's P/E ratio is -0.39. In terms of profitability, HRC's ROE is +0.14%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, HRC is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for HRC.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
HRC vs MHUA Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MHUA's P/E ratio is 0.25. In terms of profitability, HRC's ROE is +0.14%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, HRC is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for HRC.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
HRC vs NXGLW Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, HRC's ROE is +0.14%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, HRC is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for HRC.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
HRC vs GMVD Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HRC's ROE is +0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HRC is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for HRC.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
HRC vs GMVDW Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HRC's ROE is +0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HRC is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for HRC.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
HRC vs AVGR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HRC's ROE is +0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, HRC is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for HRC.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
HRC vs LUCYW Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, HRC's ROE is +0.14%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, HRC is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for HRC.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
HRC vs GCTK Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GCTK's P/E ratio is -0.01. In terms of profitability, HRC's ROE is +0.14%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, HRC is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for HRC.Check GCTK's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
HRC vs ATRS Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ATRS has a market cap of 0. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATRS's P/E ratio is 14.95. In terms of profitability, HRC's ROE is +0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, HRC is less volatile compared to ATRS. This indicates lower risk in terms of short-term price fluctuations for HRC.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
HRC vs ALOG Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, ALOG has a market cap of 0. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ALOG's P/E ratio is 40.93. In terms of profitability, HRC's ROE is +0.14%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, HRC is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for HRC.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
HRC vs IVTY Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, IVTY has a market cap of 0. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IVTY's P/E ratio is -3.80. In terms of profitability, HRC's ROE is +0.14%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, HRC is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for HRC.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
HRC vs APR Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, APR has a market cap of 0. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas APR's P/E ratio is 22.59. In terms of profitability, HRC's ROE is +0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, HRC is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for HRC.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
HRC vs IIN Comparison July 2026
Hill-Rom Holdings, Inc. (NYSE: HRC) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at 0. In comparison, IIN has a market cap of 0. Regarding current trading prices, HRC is priced at $155.96 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IIN's P/E ratio is 226.45. In terms of profitability, HRC's ROE is +0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, HRC is similarly volatile compared to IIN. This indicates similar risk in terms of short-term price fluctuations for HRC.Check IIN's competition here